April 23, 2017 6:19 AM ET


Company Overview of INO Therapeutics LLC

Company Overview

INO Therapeutics LLC provides inhaled nitric oxide, an inhaled drug for treating hypoxic respiratory failure in newborns greater than 34 weeks gestational age. The company also offers INOmax DSIR line of delivery systems. It improves oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. INO Therapeutics LLC was formerly known as INOCO, Inc. and changed its name to INO Therapeutics LLC in November 2003. The company was founded in 1998 and is ...

53 Frontage Road

Perryville III Corporate Park

Third Floor

P.O. Box 9001

Hampton, NJ 08827-9001

United States

Founded in 1998





Key Executives for INO Therapeutics LLC

INO Therapeutics LLC does not have any Key Executives recorded.

INO Therapeutics LLC Key Developments

Therapeutics, Inc. Enters into Second Amendment to the Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement with INO Therapeutics LLC

On July 27, 2015, Bellerophon Pulse Technologies LLC entered into a second amendment to the Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement, dated as of February 9, 2014, between Pulse Technologies and INO Therapeutics LLC. The parties entered into the Cross-License in connection with the Company’s spin-out from Ikaria. The Amendment expands the scope of the Company’s license from INO Therapeutics under the Cross-License to allow the Company to develop its INOpulse program for the treatment of three additional cardiopulmonary diseases: chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Subject to the terms set therein, the Amendment also provides that the Company will pay INO Therapeutics a royalty equal to 5% of Net Sales (as defined in the Amendment) of any commercialized products for the three additional indications.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact INO Therapeutics LLC, please visit www.inomax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.